ReviewCurrent opinion in ophthalmology2019
Precision medicine to prevent glaucoma-related blindness.
Review in Current opinion in ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Biomechanical Relationships Between the Aqueous Veins and Perilimbal Sclera During Intraocular Pressure Regulation.Translational vision science & technology · 2025Article
- Current perspectives in tackling glaucoma blindness.Indian journal of ophthalmology · 2025Review
- Stem cell-based approaches for glaucoma treatment: a mini review.Open life sciences · 2025Review
- Association of Matrix Metalloproteinases Polymorphisms with Glaucoma Risk, Glaucoma Phenotype, and Response to Treatment with Selective Laser Trabeculoplasty or Latanoprost.International journal of molecular sciences · 2024Article
- Predicting Glaucoma Before Onset Using a Large Language Model Chatbot.American journal of ophthalmology · 2024Article
- Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance.Handbook of experimental pharmacology · 2024Review
- 3D imaging of aqueous veins and surrounding sclera using a dual-wavelength photoacoustic microscopy.Biomedical optics express · 2023Article
- Article
- Tunable degrees of neurodegeneration in rats based on microsphere-induced models of chronic glaucoma.Scientific reports · 2022Article
- Can Nutrition Play a Role in Ameliorating Digital Eye Strain?Nutrients · 2022Review
- Article
- Recent Advances and the Mechanism of Astaxanthin in Ophthalmological Diseases.Journal of ophthalmology · 2022Review
- Oral administration of a dual ETMolecular vision · 2022Article
- Method for the biomechanical analysis of aqueous veins and perilimbal sclera by three-dimensional photoacoustic imaging and strain field calculation.Scientific reports · 2021Article
- Article
- Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography.Pharmaceutics · 2021Article
- Article
- Microinvasive Glaucoma Surgery: A Review of Schlemm's Canal-Based Procedures.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
- Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.JAMA ophthalmology · 2021Article
- Minimally Invasive Glaucoma Surgery: What Do We Know? Where Should We Go?Translational vision science & technology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
purpose of reviewApproximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT
findingsThe current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.